Share on facebook Share on Twitter Share on Google Plus Share This

Gastroenterology

Back to Results

Jatin Roper, MD accepting new patients


Book an Appointment

Don't see an appointment time? Request directly with the clinic.

Request Appointment

Overview

Programs + Specialties
Research Interests Colorectal cancer, intestinal stem cells, mouse models of colorectal cancer, intestinal biology, regulation of intestinal cancer by Akt/PKB and Tpl2 kinase, intestinal epithelial cells, cancer stem cells, intestinal organoids, CRISPR/Cas9 gene editing
Training + Education Boston University School of Medicine; NYU School of Medicine; Tufts Medical Center
Board Certifications Internal Medicine, Gastroenterology and Hepatology
NPI # 1124273461
Gender Male
Language(s) Hindi, Spanish
Accepted Insurances View Accepted Insurances at Tufts MC + Floating Hospital

Locations + Directions

Tufts Medical Center
Proger Building, 3rd Floor
800 Washington St.
Box 233
Boston, MA 02111
Phone #: 617-636-5883
Fax #: 617-636-4505

Honors + Awards


2017, BPoD – Biomedical Picture of the Day
2017, Vector Laboratories Photo Contest Winner
2016, Koch Institute for Integrative Cancer Research at MIT Image Award
2015, AGA Future Leaders Program Member, American Gastroenterological Association
2013, V Scholar Award, V Foundation
2012, AGA Academic Skills Workshop Grant Recipient, American Gastroenterological Association
2011, Investing in the Future: Clinical Research in IBD Award, American Gastroenterological Association (AGA) Institute
2011, Fellowship2Leadership Gastroenterology/Hepatology Fellows’ Travel Grant 2011 Salix Pharmaceuticals
2011, ACG Travel Award for Outstanding Clinical Research Presentation 2011 North American Conference for GI Fellows, American College of Gastroenterology
2011, Oral presentation, Gastrointestinal Oncology Section, Distinguished Abstracts Plenary Digestive Disease Week
2011, Clinical Research in IBD Award, American Gastroenterological Association
2010, 2nd place for Outstanding Poster, Tufts Medical Center Cancer Center Retreat
2006, Michael Saperstein Medical Scholar, New York University Department of Medicine
2005, Empire Clinical Research Investigator Program (ECRIP) Award
2004, Alumni Association Award, Boston University School of Medicine
2001, David E. Rogers Fellowship, New York Academy of Medicine
2001, Magna Cum laude, Boston University

Publications + National Presentations

1. Roper, J., Francois, F., Shue, P.L., Mourad, M., Pei, Z., Olivares, A.Z., Perez-Perez, G.I., Tseng, C.H., Blaser, M.J. Leptin and ghrelin in relation to Helicobacter pylori status in male veterans. Journal of Clinical Endocrinology and Metabolism 2008; 93(6):2350-7. PMID: 18397989, PMCID: 2435636

2. Roper, J., Richardson, M.P., Wang, W.V., Georgeon Richard, L., Chen, W., Coffee, E.M., Sinnamon, M.J., Lee, L., Chen, P., Bronson, R.T., Martin, E.S., Hung, K.E. The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer. PLoS ONE 2011;6(9):e25132. PMID: 21966435, PMCID: 3180374

3. Roper, J., Hung, K.E. Priceless "GEMMs": Genetically Engineered Mouse Models for Colorectal Cancer Drug Development. Trends in Pharmacological Sciences 2012 Aug;33(8):449-55. PMID: 22739258.

4. Martin, E.S., Belmont, P.J., Sinnamon, M.J., Georgeon Richard, L., Yuan, J., Coffee, E., Roper, J., Lee, L., Heidari, P., Lunt, S.Y., Goel, G., Ji, C., Xie, J., Xie, T., Lamb, J., Weinrich, S., Vanarsdale, T.L., Bronson, R.T., Xavier, R.J., Vander Heiden, M., Kan, J., Mahmood, U., Hung, K.E. Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation. Clin Cancer Res. 2013 Jun 1;19(11):2929-40. PMID: 23403635

5. Coffee, E.M., Faber, A.C., Roper, J., Sinnamon, M.J., Goel, G., Keung, L., Wang, W.V., Vecchione, L., de Vriendt, V., Weinstein, B.J., Bronson, R.T., Tejpar, S., Xavier, R.J., Engelman, J.A., Martin, E.S., Hung, K.E. Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. Clin Cancer Res. 2013 May 15;19(10):2688-98. PMID: 23549875, NIHMS 461193

6. Faber A.C., Coffee E.M., Costa C., Dastur A., Ebi H., Hata A.N., Yeo A.T., Edelman E.J., Song Y., Tam A.T., Boisvert J.L., Milano R.J., Roper J., Kodack D.P., Jain R.K., Corcoran R.B., Rivera M.N., Ramaswamy S., Hung K.E., Benes C.H., Engelman J.A. mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discov. 2014 Jan;4(1):42-52. PMID: 24163374

7. Roper J., Sinnamon M.J., Coffee E.M., Belmont P., Keung L., Georgeon-Richard L., Wang W.V., Faber A.C., Yun J., Yilmaz O.H., Bronson R.T., Martin E.S., Tsichlis P.N., Hung K.E. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett. 2014 Jun 1;347(2):204-11. PMID: 24576621, PMCID: 4118771

8. Roper J., Martin E.S., Hung K.E. Genetically Engineered Mouse Models of Colorectal Carcinoma to Enable Translational Biology and Drug Development. Curr Protoc Pharmacol. 2014 Jun 16;65:14.29.1-14.29.10. PMID: 24934606

9. Belmont P.J., Budinska E., Jiang P., Sinnamon M.J., Coffee E., Roper J., Xie T., Rejto P.A., Derkits S., Sansom O.J., Delorenzi M., Tejpar S., Hung K.E., Martin E.S.. Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease. Dis Model Mech. 2014 Jun;7(6):613-23. PMID: 24742783, PMCID: 4036469

10. Paul S., Sepehr G.J., Weinstein B., Roper J. Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Dig Dis Sci. 2014 Nov;59(11):2831-5. PMID: 25108519

11. Belmont P.J., Jiang P., McKee T.D., Xie T., Isaacson J., Baryla N.E., Roper J., Sinnamon M.J., Lee N.V., Kan J.L., Guicherit O., Wouters B.G., O'Brien C.A., Shields D., Olson P., VanArsdale T., Weinrich S.L., Rejto P., Christensen J.G., Fantin V.R., Hung K.E., Martin E.S. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Sci Signal. 2014 Nov 11;7(351):ra107. PMID: 25389372.

12. Roper J., Martin E.S., Hung K.E. Genetically Engineered Mouse Models of Colorectal Carcinoma to Enable Translational Biology and Drug Development. Current Protocols Pharmacology. 2014 Jun 16;65:14.29.1-14.29.10. PMID: 24934606

13. Belmont P.J., Budinska E., Jiang P., Sinnamon M.J., Coffee E., Roper J., Xie T., Rejto P.A., Derkits S., Sansom O.J., Delorenzi M., Tejpar S., Hung K.E., Martin E.S. Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease. Dis Model Mech. 2014 Jun;7(6):613-2 PMID: 24742783, PMCID: 4036469

14. Paul S., Sepehr G.J., Weinstein B., Roper J. Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Digestive Disease Sciences. 2014 Nov;59(11):2831-5. PMID: 25108519

15. Belmont P.J., Jiang P., McKee T.D., Xie T., Isaacson J., Baryla N.E., Roper J., Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Science Signaling. 2014 Nov 11;7(351):ra107. PMID: 25389372

16. Golovko D., Kedrin D., Yilmaz Ö.H., Roper J. Colorectal cancer models for novel drug discovery. Expert Opinion Drug Discovery. 2015;10(11):1217-29 PMID: 26295972, PMCID: 4872297

17. Yun J., Mullarky E., Lu C., Bosch K.N., Kavalier A., Rivera K., Roper J., Chio I.I., Giannopoulou E.G., Rago C., Muley A., Asara J.M., Paik J., Elemento O., Chen Z., Pappin D.J., Dow L.E., Papadopoulos N., Gross S.S., Cantley L.C. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH. Science. 2015 Dec 11;350(6266):1391-6 PMID: 26541605, PMCID: 4778961

18. Beyaz S.*, Mana M.D.*, Roper J.*, Kedrin D., Saadatpour A., Hong S.J., Bauer-Rowe K.E., Xifaras M.E., Akkad A., Pinello L., Katz Y., Shinagare S., Abu-Remaileh M., Lamming D., Guo G., Selig M., Nielsen G.P., Gupta N., Ferrone C., Deshpande V., Yuan G.C., Orkin S.H., Sabatini D.M., Yilmaz Ö.H. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. Nature. 2016 Mar 3; 531(7592):53-8. PMID: 26935695, PMCID: 4846772

*Equal contributors, co-first authors • Preview: Luo C, Puigserver P. Stem cells: Dietary fat promotes intestinal dysregulation. Nature. 2016 Mar 3; 531(7592):42-43.
• Preview: Haller S., Jasper H. You are what you eat: linking high-fat diet to stem cell dysfunction and tumorigenesis. Cell Stem Cell. 2016 May 5;18(5):564-6.

19. Kedrin D., Chandrahas Gandhi S.C, Wolf M., Roper J., Yilmaz Ö.H., Corey K., Khalili H., Stanford F., Gala M. Bariatric Surgery Prior to Index Screening Colonoscopy is associated with a decreased risk of colorectal adenomas in obese individuals. Clinical and Translational Gastroenterology. 2017 Feb 9;8(2):e73. PMID: 28181993, PMCID: 538774812.

20. Roper J.*, Tammela T.*, Cetinbas N.M., Akkad A., Roghanian A., Rickelt S., Almeqdadi M., Wu K., Oberli M., Sánchez-Rivera F.J., Park Y., Liang X., Eng G., Azimi R., Kedrin D., Neupane R., Beyaz S., Sicinska E.T., Bass A., Suarez Y., Yoo J., Chen L., Taylor M.S., Zukerberg L., Katajisto P., Tsichlis P.N., Lees J., Deshpande V., Chen J., Hynes R.O., Langer R., Bhutkar A., Jacks T., Yilmaz Ö.H. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology. 2017 http://dx.doi.org/10.1038/nbt.3836
PMID: 28459449

*Equal contributors, co-first authors • Gut Organoid Transplants Produce Colorectal Cancer in Mice. The Scientist, May 1, 2017. http://www.the-scientist.com/?articles.view/articleNo/49321/title/Gut-Organoid-Transplants-Produce-Colorectal-Cancer-in-Mice/
• New model could speed up colon cancer research. MIT News, May 1, 2017. http://news.mit.edu/2017/crispr-model-speed-colon-cancer-research-0501
• New MIT Mouse Model Using CRISPR Technology Could Speed Up Colon Cancer Research. Colon Cancer News Today, May 2, 2017. https://coloncancernewstoday.com/2017/05/02/colon-cancer-research-mit-mouse-model-crispr-genome-editing/
• New Lab Technique Could Lead to Better Colon Cancer Therapies. Tufts Medical Center News & Events, May 2, 2017. https://www.tuftsmedicalcenter.org/News-Events-Media/News/Web/Colon-Cancer-Therapies.aspx
• Tailored Mouse Models. Nature Reviews Cancer 17, 395 (2017) https://www.nature.com/nrc/journal/v17/n7/pdf/nrc.2017.45.pdf

21. Roper J., Yilmaz Ö.H. Preview: Metabolic Teamwork in the Stem Cell Niche. Cell Metabolism. 2017 http://dx.doi.org/10.1016/j.cmet.2017.04.019 PMID: 28467944

22. Roper J. Tammela T., Almeqdadi M., Santos S., Akkad A., Yilmaz Ö.H. Colonoscopy-based colorectal cancer modeling with CRISPR-Cas9 genome editing and organoid transplantation. Nature Protocols. 2017 Accepted Manuscript.

20. Roper J.*, Tammela T.*, Cetinbas N.M., Akkad A., Roghanian A., Rickelt S., Almeqdadi M., Wu K., Oberli M., Sánchez-Rivera F.J., Park Y., Liang X., Eng G., Azimi R., Kedrin D., Neupane R., Beyaz S., Sicinska E.T., Bass A., Suarez Y., Yoo J., Chen L., Taylor M.S., Zukerberg L., Katajisto P., Tsichlis P.N., Lees J., Deshpande V., Chen J., Hynes R.O., Langer R., Bhutkar A., Jacks T., Yilmaz Ö.H. In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nature Biotechnology. 2017 http://dx.doi.org/10.1038/nbt.3836
PMID: 28459449
*Equal contributors, co-first authors • Gut Organoid Transplants Produce Colorectal Cancer in Mice. The Scientist, May 1, 2017. http://www.the-scientist.com/?articles.view/articleNo/49321/title/Gut-Organoid-Transplants-Produce-Colorectal-Cancer-in-Mice/
• New model could speed up colon cancer research. MIT News, May 1, 2017. http://news.mit.edu/2017/crispr-model-speed-colon-cancer-research-0501
• New MIT Mouse Model Using CRISPR Technology Could Speed Up Colon Cancer Research. Colon Cancer News Today, May 2, 2017. https://coloncancernewstoday.com/2017/05/02/colon-cancer-research-mit-mouse-model-crispr-genome-editing/
• New Lab Technique Could Lead to Better Colon Cancer Therapies. Tufts Medical Center News & Events, May 2, 2017. https://www.tuftsmedicalcenter.org/News-Events-Media/News/Web/Colon-Cancer-Therapies.aspx
• Tailored Mouse Models. Nature Reviews Cancer 17, 395 (2017)
https://www.nature.com/nrc/journal/v17/n7/pdf/nrc.2017.45.pdf

21. Roper J., Yilmaz Ö.H. Preview: Metabolic Teamwork in the Stem Cell Niche. Cell Metabolism. 2017 http://dx.doi.org/10.1016/j.cmet.2017.04.019 PMID: 28467944

22. Roper J. Tammela T., Almeqdadi M., Santos S., Akkad A., Yilmaz Ö.H. Colonoscopy-based colorectal cancer modeling with CRISPR-Cas9 genome editing and organoid transplantation. Nature Protocols. 2017 Accepted Manuscript.

Biography

Jatin Roper, MD, is the Director of the Center for Hereditary Gastrointestinal Cancer at Tufts Medical Center. He attended college and medical school at Boston University through the Seven-Year Liberal Arts/Medical Education Program, followed by residency training in Internal Medicine at NYU Medical Center and fellowship training in Gastroenterology and Hepatology at Tufts Medical Center. During his research fellowship, he used genetically engineered mouse models of cancer and immortalized murine tumor cell lines to study the roles of the PI3K/mTOR pathways and the KRAS oncogene in colorectal carcinogenesis. As a Research Affiliate at MIT, he showed that high fat diet-activated peroxisome proliferator-activated receptor delta (PPARd) signaling in intestinal stem cells and progenitors enhances tumor initiation (Nature 2016). Dr. Roper recently developed novel orthotopic transplantation and in situ CRISPR/Cas9 gene editing mouse models of colorectal cancer that recapitulate the entire adenoma-carcinoma-metastasis sequence, permit rapid assessment of gene function in cancer, and enable sequential gene mutagenesis. Furthermore, he established novel orthotopic mouse models of patient-derived colorectal cancer (Nature Biotechnology 2017).The long-term goal of his research is to understand the molecular regulation of intestinal stem cells in the context of normal physiology, cancer, and metastasis.

News, Media + Videos

Jatin Roper, MD is the Director of the Center for Hereditary Gastrointestinal Cancer and Assistant Professor of Medicine in the Division of Gastroenterology and Molecular Oncology Research Institute (MORI) at Tufts Medical Center.

New lab technique developed in part by team at Tufts MC could lead to better therapies for colorectal cancer.

Learn about this research
Jatin Roper, MD is a gastroenterologist at Tufts Medical Center in downtown Boston, MA.

Dr. Jatin Roper provides updates on Colorectal Cancer Syndromes on QuantiaMD.

Watch Dr. Roper's presentation on colorectal cancer
A drawing of gastro for Tufts Medical Center in downtown Boston, MA.

Jatin Roper, MD is co-lead author of potentially groundbreaking research into the effect of a high-fat diet and colorectal cancer.

Read more about the study
Jatin Roper, MD is a gastroenterologist at Tufts Medical Center in downtown Boston, MA.

Tufts Medical Center launches multidisciplinary Center for Hereditary Gastrointestinal Cancers.

New Hereditary GI Cancers Program